Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524879-23-00

Enrollment

Registered

2026-06-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Marginal Zone Lymphoma

Brief summary

CR rate (CRR) determined 4 weeks after the end of treatment (after 12 cycles of treatment or in the case of early termination at the time point of the early termination visit)

Detailed description

Overall response rate (ORR) after12 cycles of treatment, Best response (BR): CR and ORR, Time to best response: CR, ORR, Time to first response: CR, ORR, Progression free survival (PFS), Time to treatment failure (TTF), Duration of Response (DR), Cause specific survival (CSS), Overall survival (OS), Quality of life, Safety

Interventions

DRUGTepkinly 4 mg/0.8 ml solution for injection

DRUGTepkinly 48 mg solution for injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
CR rate (CRR) determined 4 weeks after the end of treatment (after 12 cycles of treatment or in the case of early termination at the time point of the early termination visit)	—

Secondary

Measure	Time frame
Overall response rate (ORR) after12 cycles of treatment, Best response (BR): CR and ORR, Time to best response: CR, ORR, Time to first response: CR, ORR, Progression free survival (PFS), Time to treatment failure (TTF), Duration of Response (DR), Cause specific survival (CSS), Overall survival (OS), Quality of life, Safety	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 20, 2026